Sarah Cappuyns (@cappuynssarah) 's Twitter Profile
Sarah Cappuyns

@cappuynssarah

MD PhD researcher in digestive oncology @UZLeuven and @Onco_KULeuven. FWO PhD fellow strategic basic research. Visiting researcher @MountSinaiLiver and @IDIBAPS

ID: 1198243788289986560

calendar_today23-11-2019 14:16:09

245 Tweet

352 Followers

386 Following

ILCA (@ilcanews) 's Twitter Profile Photo

As we approach #ILCA24, we want to know - do you use X/Twitter to discuss #livercancer research? 🧑‍🔬 Share your thoughts and join us on 17-19 Oct. in Toronto for an engaging session on maximizing the impact of your research on social media. Register now: shorturl.at/pn8V4

Sarah Cappuyns (@cappuynssarah) 's Twitter Profile Photo

Great to see so many young colleagues at #ILCA2024 in Toronto! Also, join us for the Young ILCA session on Science and Social Media later this afternoon. I promise it will be worth your while ! ILCA Arndt Vogel Angela Lamarca David James Pinato 🇺🇦 Elliot Tapper Lorenza Rimassa

Valerie Chew (@valeriechew29) 's Twitter Profile Photo

It's important to #communicate and #tweet about our #research and #science these days! Sharing session on how to do this effectively is both unique and fun! #yilca #ilca24 Arndt Vogel Antonio D'Alessio Lorenza Rimassa Sarah Cappuyns Angela Lamarca ILCA

Sarah Cappuyns (@cappuynssarah) 's Twitter Profile Photo

❗️Pathological response predicts RFS after neoadjuvant IO in #HCC❗️ ❓Can we translate this to preTx biomarkers in advanced HCC somehow❓#holygrail 👉 A rich source of data for translation research.. curious to see more in the future 👏 Antonio D'Alessio David James Pinato 🇺🇦 ILCA

Arndt Vogel (@arndtvogel) 's Twitter Profile Photo

🔥off the press: Characterization of Tumor Responses in HCC Treated with Lenvatinib in REFLECT Liver Cancer doi.org/10.1159/000540… 👉ORR of 18.8% by RECIST v1.1 & 40.6% by mRECIST w/ Lenvatinib 🧐Response matters in HCC (even more today) ESMO - Eur. Oncology EASL Education ILCA #livertwitter

🔥off the press: Characterization of Tumor Responses in HCC Treated with Lenvatinib in REFLECT
Liver Cancer
doi.org/10.1159/000540…
👉ORR of 18.8% by RECIST v1.1 & 40.6% by mRECIST w/ Lenvatinib
🧐Response matters in HCC (even more today)
<a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/EASLedu/">EASL Education</a> <a href="/ILCAnews/">ILCA</a> #livertwitter
ILCA (@ilcanews) 's Twitter Profile Photo

❗️Save the Date: ILCA 2025 Annual Conference 📅 Nov. 19–21, 2025 📍 Hong Kong ➡️ilcalive.org/annual-confere… In 2025, we’re bringing the ILCA Annual Conference back to Asia! Join liver cancer specialists, researchers, and health professionals worldwide.🌏Stay tuned!

❗️Save the Date: ILCA 2025 Annual Conference
📅 Nov. 19–21, 2025
📍 Hong Kong
➡️ilcalive.org/annual-confere…

In 2025, we’re bringing the ILCA Annual Conference back to Asia! Join liver cancer specialists, researchers, and health professionals worldwide.🌏Stay tuned!
Timon Vandamme (@timonv) 's Twitter Profile Photo

Today is a good day! Our new paper on a Belgian cohort of 283 high grade neuroendocrine neoplasms receives Thor Halfdanarson's stamp of approval. More on NET G3 vs NEC, functional imaging,... through erc.bioscientifica.com/view/journals/… NETwerk Willem Lybaert

Gertjan Rasschaert (@gjras) 's Twitter Profile Photo

Immunosensitivity cuts across mismatch repair status in colorectal cancer Our preview article on the recent Acha-Sagredo et al. has been published today in Cancer Cell. shorturl.at/uJ8av

Immunosensitivity cuts across mismatch repair status in colorectal cancer

Our preview article on the recent Acha-Sagredo et al. has been published today in <a href="/Cancer_Cell/">Cancer Cell</a>. 

shorturl.at/uJ8av
Sarah Cappuyns (@cappuynssarah) 's Twitter Profile Photo

I recently had a chat with Jeroen Dekervel about one of our favourite topics… Biomarkers in HCC: why we need them, and why they are so difficult to identify.. Have a listen!! 🎧 🎙️👇